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CNS INFLAMMATION OTHER THAN MULTIPLE
SCLEROSIS: HOW LIKELY IS DIAGNOSIS?
The incidence, diagnostic landscape, and workload
impact of CNS inflammatory diseases other than mul-
tiple sclerosis (MS) (CIDOMS) in a tertiary setting is
unknown. We describe a retrospective case series of
64 patients identified over a 2-year period (2009–
2010) at the Wessex Neurological Centre in the
United Kingdom, accounting for 4% of all patients
seen at the center. As expected, neurosarcoidosis
and neuromyelitis optica (NMO) were the most
common diagnoses reached (14% each); other diag-
noses singly accounted for ,10%. However, the
likeliest diagnostic outcome (strikingly, in 25%)
was nondiagnosis, despite intensive investigation
and a mean follow-up period of 3 years. Undiagnosed
patients with CIDOMS represented the largest work-
load of the neurology center.
The Wessex Neurological Centre is a typical regional
neurologic service with a catchment population of ;3
million in southern England and on-site expertise
in neurology, neurosurgery, neuropathology, neuro-
physiology, neuroradiology, neuropsychology, neuro-
rehabilitation, and neurophysiotherapy, across which
specialist interest in neuroinflammatory disease is
adequately represented. The study was approved
by the University of Southampton’s Ethics and
Research Governance. A diagnosis of CIDOMS
was made when there was unequivocal evidence of
CNS inflammation (with certainty of an inflamma-
tory etiology based on clinical, radiologic, CSF,
and other laboratory findings) in the absence of
MS or clinically isolated syndrome (CIS). Published
diagnostic criteria (or, in their absence, published
consensus opinions) were utilized to establish spe-
cific CIDOMS diagnoses (tables e-1 and e-2 on the
Neurology® Web site at Neurology.org). MS and CIS
were diagnosed according to established criteria.1,2
Detailed evaluation was conducted regarding resource
utilization, including inpatient episode duration,
imaging, invasive procedures, neurophysiology, non-
neurology specialist reviews, and laboratory tests. In
order to provide a sense of proportion to figures, a
similar analysis was performed in patients admitted
during the same period whose final diagnosis was
MS. Further method details are available online
(e-Methods).
From a total of 1,525 patients admitted to the ter-
tiary neurology center, 81 had a working diagnosis of
CIDOMS, which was maintained in 64 cases as a
final diagnosis. This represents an incidence rate of
11 cases of CIDOMS per million person-years. Sev-
enteen patients with an initial working diagnosis
of CIDOMS received a diagnosis of MS by the end
of the follow up-period. A breakdown of individual
CIDOMS diagnoses is given in table 1 (for more detail,
see tables e-1 and e-2).
Despite their small number (n 5 64) in compar-
ison with MS patients (n 5 167), patients with
CIDOMS required disproportionately longer inpa-
tient stays, more intensive care, and larger numbers
of investigations (see table 1 and figure e-1, p ,
0.001 across all categories). Naturally, this resulted
in higher costs (£520,409.18 vs £259,941.51, i.e.,
twice as much, p , 0.0001, see table e-3 and figure
e-2). Among patients with CIDOMS, those without a
diagnosis represented the largest workload of the neurol-
ogy center, since they collectively needed the longest
inpatient stay and the greatest number of investigations
(see table 1).
The definition of CIDOMS did not include CIS,
and it may be argued that cases of CIS with low risk
of conversion to MS (with normal MRI and CSF1)
may turn out to have CIDOMS. None of the pa-
tients with a diagnosis of CIS converted to a diag-
nosis of CIDOMS in this study, but this may need
longer follow-up, as illustrated by a recent case
series.3 However, categorization of low-risk CIS
with CIDOMS and high-risk CIS with MS main-
tains nondiagnosis as the most common outcome in
patients with CIDOMS (16 out of 78, i.e., 21%),
and maintains patients with CIDOMS as still more
resource-intensive than patients with MS (data not
shown).
Two undiagnosed patients with CIDOMS had a
clinical phenotype that resembled NMO spectrum
disorder, though not typical (last 2 cases in table
e-2). Restriction of anti-aquaporin antibodies to
the CSF,4 anti-aquaporin-4 antibody assay sensitiv-
ity,5,6 and antimyelin oligodendrocyte glycoprotein
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antibodies7 may be explanations. Yet again, a sensitiv-
ity analysis excluding these patients did not change
conclusions.
Collectively CIDOMS are common and consist
of up to 25% of the neurologic practice pertaining
to inflammatory CNS disorders. The data highlight
the importance of education regarding the diagno-
sis and treatment of these disorders. The striking
finding that one-quarter of CIDOMS remained
undiagnosed means that, in the absence of a diagno-
sis of neurosarcoidosis or NMO, an unclassified
inflammatory disease is eventually more likely than other
rarer diagnoses, which singly accounted for fewer than
10%. Broader serologic testing for individually rare
antibodies and discovery of novel biomarkers
should facilitate more rapid diagnoses in unclassi-
fied cases. Meanwhile, in the absence of a diagno-
sis, consensus guidelines to help recognition of
antibody vs T-cell–mediated neuroinflammatory
disorders will enable a rational empirical approach
to treatment based on the likely underlying path-
ophysiologic mechanism.
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Table 1 Number, percentage, and biennial total resource use of patients with CIDOMS by their final diagnostic categories
Diagnostic category Number %
Total days in
hospital
Days on
ICU
All
imaging MRIs
Invasive
procedures Neurophysiology
Specialist
reviews
Laboratory
tests
Unclassified 16a 25a 295.5a 0 75a 30a 31a 13a 10a 994
Neurosarcoidosis 9 14 278 13.5 59 18 19 4 5 1,021a
Neuromyelitis optica 9 14 117 0 18 6 4 2 1 420
Cerebral vasculitis 4 6 246.5 2 52 10 16 2 9 707
Anti-VGKC encephalitis 4 6 93.5 0 19 3 6 4 1 227
ADEM 3 5 75.5 9 15 5 4 1 0 327
Postinfective 3 5 32 0 9 3 3 3 0 150
Anti-NMDA receptor
encephalitis
2 3 216.5 39a 18 3 6 4 2 584
Paraneoplasia in lymphoma 2 3 87.5 0 27 8 5 4 0 326
Opsoclonus-myoclonus 2 3 53 0 6 2 2 0 0 134
Neuro-Behçet 2 3 31.5 0 7 3 3 2 2 92
Atypical MS 2 3 13.5 0 4 3 3 2 1 95
CRION 1 2 10.5 0 3 2 3 2 1 81
Anti-Hu syndrome 1 2 17 0 4 0 0 0 2 38
Lymphocytic hypophysitis 1 2 7 0 2 0 3 0 0 61
Neuro-Sjögren 1 2 4 0 3 3 1 2 1 30
Stiff person syndrome 1 2 9 0 0 0 0 0 0 15
Radiologically isolated
syndrome
1 2 0.5 0 1 1 1 0 0 15
Total 64 100 1,588 63.5 322 100 110 45 35 5,317
MS (for comparison) 167 100 689.5 0 57 109 106 43 5 3,735
CIS: low and high risk (for
comparison)
25 100 122 0 25 11 21 12 1 496
Abbreviations: ADEM 5 acute disseminated encephalomyelitis; CIDOMS 5 CNS inflammatory diseases other than multiple sclerosis; CIS 5 clinically isolated
syndrome; CRION 5 chronic relapsing inflammatory optic neuritis; ICU 5 intensive care unit; MS 5 multiple sclerosis; VGKC 5 voltage-gated potassium channel.
Invasive procedures included catheter cerebral angiogram; lumbar puncture; biopsy of brain, nerve, skin, pinna, or bone marrow; gastroscopy;
bronchoscopy; or flexisigmoidoscopy.
a Highest numbers.
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Complete the AAN 2014 Neurology Compensation and
Productivity Survey by May 9
The AAN launched its second annual Neurology Compensation and Productivity Survey in March
and needs practicing US members and their practices to contribute their data. It is critical that all
US neurologists and practice managers participate in the survey to ensure the most accurate and
authoritative data representing the US neurology landscape. Visit AAN.com/view/2014NeuroSurvey
to review preparation documents, including an FAQ and Quick Start Guide. Complete the survey
by May 9 and get free access to the online results and the Neurology Compensation and Productivity
Report, available in early July 2014. The cost to access the data and report for nonparticipants is
$600 for AAN members and $1200 for nonmembers.
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The editors encourage comments about recent articles through WriteClick:
Go to www.neurology.org and click on the “WriteClick” tab at the top of the page. Responses will
be posted within 72 hours of submission.
Before using WriteClick, remember the following:
• WriteClick is restricted to comments about studies published in Neurology within the last eight
weeks
• Read previously posted comments; redundant comments will not be posted
• Your submission must be 200 words or less and have a maximum of five references; reference
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